Your browser doesn't support javascript.
loading
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi, Justina X; Zhang, Jiajia; Ji, Zhicheng; Vaghasia, Ajay; Zhang, Boyang; Hsiue, Emily Han-Chung; Mog, Brian J; Hou, Wenpin; Justesen, Sune; Blosser, Richard; Tam, Ada; Anagnostou, Valsamo; Cottrell, Tricia R; Guo, Haidan; Chan, Hok Yee; Singh, Dipika; Thapa, Sampriti; Dykema, Arbor G; Burman, Poromendro; Choudhury, Begum; Aparicio, Luis; Cheung, Laurene S; Lanis, Mara; Belcaid, Zineb; El Asmar, Margueritta; Illei, Peter B; Wang, Rulin; Meyers, Jennifer; Schuebel, Kornel; Gupta, Anuj; Skaist, Alyza; Wheelan, Sarah; Naidoo, Jarushka; Marrone, Kristen A; Brock, Malcolm; Ha, Jinny; Bush, Errol L; Park, Bernard J; Bott, Matthew; Jones, David R; Reuss, Joshua E; Velculescu, Victor E; Chaft, Jamie E; Kinzler, Kenneth W; Zhou, Shibin; Vogelstein, Bert; Taube, Janis M; Hellmann, Matthew D; Brahmer, Julie R; Merghoub, Taha.
Affiliation
  • Caushi JX; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Zhang J; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Ji Z; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Vaghasia A; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Zhang B; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Hsiue EH; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Mog BJ; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Hou W; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
  • Justesen S; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Blosser R; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Tam A; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Anagnostou V; Ludwig Center and Howard Hughes Medical Institute at Johns Hopkins, Baltimore, MD, USA.
  • Cottrell TR; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Guo H; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Chan HY; Ludwig Center and Howard Hughes Medical Institute at Johns Hopkins, Baltimore, MD, USA.
  • Singh D; Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Thapa S; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
  • Dykema AG; Immunitrack, Copenhagen, Denmark.
  • Burman P; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Choudhury B; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Aparicio L; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Cheung LS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Lanis M; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Belcaid Z; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • El Asmar M; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Illei PB; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Wang R; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Meyers J; Ontario Institute for Cancer Research, Queens University, Kingston, Ontario, Canada.
  • Schuebel K; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Gupta A; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Skaist A; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Wheelan S; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Naidoo J; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Marrone KA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Brock M; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Ha J; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Bush EL; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Park BJ; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Bott M; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Jones DR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Reuss JE; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Velculescu VE; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Chaft JE; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Kinzler KW; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Zhou S; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Vogelstein B; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Taube JM; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Hellmann MD; The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
  • Brahmer JR; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Merghoub T; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
Nature ; 596(7870): 126-132, 2021 08.
Article de En | MEDLINE | ID: mdl-34290408
ABSTRACT
PD-1 blockade unleashes CD8 T cells1, including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell responses. Single-cell transcriptomics have revealed global T cell dysfunction programs in tumour-infiltrating lymphocytes (TIL). However, the majority of TIL do not recognize tumour antigens2, and little is known about transcriptional programs of MANA-specific TIL. Here, we identify MANA-specific T cell clones using the MANA functional expansion of specific T cells assay3 in neoadjuvant anti-PD-1-treated non-small cell lung cancers (NSCLC). We use their T cell receptors as a 'barcode' to track and analyse their transcriptional programs in the tumour microenvironment using coupled single-cell RNA sequencing and T cell receptor sequencing. We find both MANA- and virus-specific clones in TIL, regardless of response, and MANA-, influenza- and Epstein-Barr virus-specific TIL each have unique transcriptional programs. Despite exposure to cognate antigen, MANA-specific TIL express an incompletely activated cytolytic program. MANA-specific CD8 T cells have hallmark transcriptional programs of tissue-resident memory (TRM) cells, but low levels of interleukin-7 receptor (IL-7R) and are functionally less responsive to interleukin-7 (IL-7) compared with influenza-specific TRM cells. Compared with those from responding tumours, MANA-specific clones from non-responding tumours express T cell receptors with markedly lower ligand-dependent signalling, are largely confined to HOBIThigh TRM subsets, and coordinately upregulate checkpoints, killer inhibitory receptors and inhibitors of T cell activation. These findings provide important insights for overcoming resistance to PD-1 blockade.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Régulation de l'expression des gènes / Lymphocytes TIL / Carcinome pulmonaire non à petites cellules / Inhibiteurs de points de contrôle immunitaires / Tumeurs du poumon / Antigènes néoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Nature Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Régulation de l'expression des gènes / Lymphocytes TIL / Carcinome pulmonaire non à petites cellules / Inhibiteurs de points de contrôle immunitaires / Tumeurs du poumon / Antigènes néoplasiques Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Nature Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...